

## SUPPLEMENTARY MATERIAL

### **Structural variants linked to Alzheimer's Disease and other common age-related clinical and neuropathologic traits**

Ricardo A Vialle<sup>1</sup>, Katia de Paiva Lopes<sup>1</sup>, Yan Li<sup>1</sup>, Bernard Ng<sup>1</sup>, Julie A Schneider<sup>1</sup>, Aron S Buchman<sup>1</sup>, Yanling Wang<sup>1</sup>, Jose M Farfel<sup>1</sup>, Lisa L Barnes<sup>1</sup>, Aliza P Wingo<sup>2,3</sup>, Thomas S Wingo<sup>4</sup>, Nicholas T Seyfried<sup>5</sup>, Philip L De Jager<sup>6</sup>, Chris Gaiteri<sup>1,7</sup>, Shinya Tasaki<sup>1</sup>, David A Bennett<sup>1</sup>

<sup>1</sup> Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA

<sup>2</sup> Department of Psychiatry, University of California, Davis CA, USA

<sup>3</sup> VA Northern California Health Care System, McClellan Park, CA, USA

<sup>4</sup> Department of Neurology, University of California, Davis, CA, USA

<sup>5</sup> Goizueta Alzheimer's Disease Research Center, Department of Neurology and Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA

<sup>6</sup> Department of Neurology, College of Physicians and Surgeons, Columbia University and the New York Presbyterian Hospital, New York, NY, USA

<sup>7</sup> Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA

---

**Supplementary Table 1. Demographic and clinical characteristics of study cohorts**

	ROS	MAP	ROS/MAP
<i>n</i>	529	559	1088
Age baseline, mean (SD), y	78.2 (6.8)	83.4 (5.8)	80.9 (6.8)
Age at death, mean (SD), y	88.1 (6.8)	89.8 (6.0)	89.0 (6.4)
Male sex, No. (%)	188 (35.5)	180 (32.2)	368 (33.8)
Educational level, mean (SD), y	18.1 (3.3)	14.6 (2.9)	16.3 (3.6)
Length of follow-up, mean (SD), y	9.1 (5.4)	5.5 (3.7)	7.2 (4.9)
MMSE score, median (IQR) - at baseline	29 (27.0-30.0)	28 (26.0-29.0)	28 (26.0-29.0)
MMSE score, median (IQR) - at death	24 (14.4-28.0)	25 (17.0-28.0)	25 (15.0-28.0)
Global cognition score, mean (SD) - at baseline	-0.04 (0.63)	-0.24 (0.76)	-0.14 (0.70)
Global cognition score, mean (SD) - at death	-1.00 (1.29)	-0.96 (1.16)	-0.98 (1.23)
MCI, No. (%)	121 (22.9)	154 (27.5)	275 (25.3)
Dementia, No. (%)	253 (47.8)	222 (39.7)	475 (43.7)
NIA-Reagan AD, No. (%) <sup>a</sup>	329 (62.2)	361 (64.6)	690 (63.4)
Global AD pathologic score, median (IQR)	0.67 (0.18-1.18)	0.65 (0.19-1.20)	0.67 (0.19-1.20)
Neuritic plaques score, median (IQR)	0.69 (0.03-1.31)	0.71 (0.06-1.35)	0.71 (0.05-1.34)
Diffuse plaques score, median (IQR)	0.66 (0.11-1.31)	0.54 (0.07-1.11)	0.60 (0.08-1.19)
Neurofibrillary tangles score, median (IQR)	0.38 (0.13-0.84)	0.39 (0.15-0.93)	0.39 (0.14-0.89)
Macroscopic infarcts, No. (%)	188 (35.5)	202 (36.1)	390 (35.8)
Microinfarcts, No. (%)	145 (27.4)	162 (29.0)	307 (28.2)
Neocortical Lewy bodies, No. (%)	66 (12.9)	70 (13.0)	136 (12.9)
TDP-43, No. (%) <sup>b</sup>	155 (33.6)	187 (34.8)	342 (34.3)
Hippocampal sclerosis, No. (%)	39 (7.5)	53 (9.5)	92 (8.5)
Amyloid angiopathy, No. (%) <sup>c</sup>	183 (36.3)	190 (34.2)	373 (35.2)
Atherosclerosis, No. (%) <sup>c</sup>	204 (39.0)	188 (33.7)	392 (36.3)
Arteriolosclerosis, No. (%) <sup>c</sup>	161 (30.8)	212 (38.0)	373 (34.5)

Abbreviations: AD, Alzheimer's disease; IQR, interquartile range; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NIA, National Institute on Aging; TDP-43, transactive response DNA-binding protein 43.

<sup>a</sup> Intermediate or high likelihood.

<sup>b</sup> Inclusion beyond the amygdala.

<sup>c</sup> Moderate or severe.

**Supplementary Table 2. Variables and categories of each phenotype tested**

<b>variable</b>	<b>family</b>	<b>category</b>	<b>description</b>
cogn_global_lv	Continuous	Cognition	Global cognitive function
cogng_demog_slope	Continuous	Cognition	Cognitive decline
cogng_path_slope	Continuous	Cognition	Cognitive resilience
tangles_sqrt	Continuous	Pathology	Tangle density
nft_sqrt	Continuous	Pathology	Neurofibrillary tangle
amyloid_sqrt	Continuous	Pathology	Beta-Amyloid
plaq_n_sqrt	Continuous	Pathology	Neuritic plaques
plaq_d_sqrt	Continuous	Pathology	Diffuse plaques
tdp_43_binary	Binary	Pathology	TDP-43
ci_num2_gct	Binary	Vascular Pathology	Cerebral Infarctions (Gross)
ci_num2_mct	Binary	Vascular Pathology	Cerebral Infarctions (Micro)
arteriol_scler	Continuous	Vascular Pathology	Arteriolosclerosis
caa_4gp	Continuous	Vascular Pathology	Cerebral amyloid angiopathy
cvda_4gp2	Continuous	Vascular Pathology	Cerebral Atherosclerosis
ad_dementia_status	Binary	Cognition	Alzheimer's Dementia
cog_impairment_status	Binary	Cognition	Mild cognitive impairment
ad_reagan	Binary	Pathology	NIA-Reagan diagnosis of AD
gpath	Continuous	Pathology	Global AD pathology
parksc_lv	Continuous	Motor	Global parkinsonian score
dlbany	Binary	Pathology	Lewy Body disease
r_depres_status	Binary	Depression	Major Depressive Disorder
cesdsum_lv	Continuous	Depression	Depressive symptoms (CES-D)
frailty_z_lv	Continuous	Motor	Frailty
motor10_lv	Continuous	Motor	Motor functions

**Supplementary Table 3. AD GWAS loci in LD with SVs associated with ADRD traits ( $P < 0.05$ )**

<b>AD GWAS locus</b>	<b>SV id</b>	<b>SV info</b>	<b>SV LD with lead SNP (R2)</b>	<b>Best phenotype associated with SV</b>	<b>P-value of SV-phenotype association</b>
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25745	DEL chr6:32512662 (len:-405 maf:0.310688)	0.91	Tangle density	3.74E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25747	DEL chr6:32514898 (len:-1399 maf:0.312047)	0.91	Tangle density	3.04E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25752	DEL chr6:32523647 (len:-6180 maf:0.468661)	0.59	Major Depressive Disorder	7.16E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25737	DEL chr6:32492661 (len:-60144 maf:0.449367)	0.55	Major Depressive Disorder	3.64E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25768	DEL chr6:32624892 (len:-950 maf:0.433544)	0.52	Cognitive decline	6.77E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25739	DEL chr6:32494986 (len:-336 maf:0.32361)	0.51	Cognitive decline	5.16E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25758	DEL chr6:32561955 (len:-2671 maf:0.175407)	0.51	Tangle density	6.39E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25759	DEL chr6:32571348 (len:-319 maf:0.44349)	0.50	Major Depressive Disorder	3.19E-02
chr6:32075406-33083813 (HLA-DRB5-)	DUP_4026	DUP chr6:32490722 (len:35810 maf:0.424051)	0.40	Tangle density	1.01E-02
chr6:32075406-33083813 (HLA-DRB5-)	DUP_4027	DUP chr6:32494883 (len:43223 maf:0.429928)	0.39	Major Depressive Disorder	3.28E-03
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25746	DEL chr6:32514825 (len:-26282 maf:0.19575)	0.35	Major Depressive Disorder	2.44E-02
chr6:32075406-33083813 (HLA-DRB5-)	ALU_3734	ALU chr6:32589834 (len:281 maf:0.116637)	0.35	Major Depressive Disorder	1.24E-01
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25761	DEL chr6:32592405 (len:-127 maf:0.214932)	0.35	Tangle density	2.65E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25765	DEL chr6:32622513 (len:-337 maf:0.438065)	0.32	Cerebral Infarctions (Micro)	4.03E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25763	DEL chr6:32614951 (len:-401 maf:0.438065)	0.32	Major Depressive Disorder	1.14E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25767	DEL chr6:32623524 (len:-1077 maf:0.426763)	0.31	Cognitive resilience	4.49E-02
chr6:32075406-33083813 (HLA-DRB5-)	SVA_296	SVA chr6:32514612 (len:1267 maf:0.11786)	0.30	Arteriolosclerosis	9.51E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25764	DEL chr6:32615970 (len:-4223 maf:0.304702)	0.29	Beta-Amyloid	1.42E-01
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25705	DEL chr6:32450599 (len:-86768 maf:0.310127)	0.28	Cognitive resilience	6.13E-03

chr6:32075406-33083813 (HLA-DRB5-)	INS_5722	INS chr6:32664240 (len:57 maf:0.113472)	0.28	Frailty	7.59E-02
chr6:32075406-33083813 (HLA-DRB5-)	ALU_3719	ALU chr6:32449295 (len:280 maf:0.327758)	0.27	Motor functions	5.01E-02
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25748	DEL chr6:32516620 (len:-24772 maf:0.242315)	0.27	Tangle density	2.91E-02
chr6:32075406-33083813 (HLA-DRB5-)	DUP_4025	DUP chr6:32488856 (len:35679 maf:0.26085)	0.25	Neurofibrillary tangle	1.20E-01
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25716	DEL chr6:32455073 (len:-23356 maf:0.279292)	0.23	Frailty	1.42E-01
chr6:32075406-33083813 (HLA-DRB5-)	DEL_25695	DEL chr6:32416934 (len:-105 maf:0.427667)	0.23	Major Depressive Disorder	1.69E-02
chr6:46931284-48052180 (CD2AP)	DEL_25938	DEL chr6:47564729 (len:-2187 maf:0.0691682)	0.22	Mild cognitive impairment	8.86E-02
chr7:11768758-12769593 (TMEM106B)	DEL_27662	DEL chr7:12281711 (len:-343 maf:0.424955)	0.96	Tangle density	7.72E-04
chr10:123672912-12467291 2 (PLEKHA1)	DEL_3676	DEL chr10:124216821 (len:-461 maf:0.230561)	0.23	Global parkinsonian score	1.16E-02
chr11:46880340-48057871 (CELF1)	DEL_4449	DEL chr11:47887667 (len:-535 maf:0.443942)	0.56	Cerebral Infarctions (Micro)	1.19E-02
chr11:46880340-48057871 (CELF1)	ALU_6357	ALU chr11:47806655 (len:280 maf:0.347197)	0.39	Cerebral Atherosclerosis	6.04E-02
chr11:46880340-48057871 (CELF1)	DEL_4444	DEL chr11:47563238 (len:-96 maf:0.368897)	0.39	Mild cognitive impairment	4.43E-02
chr12:113219788-11421978 8 (TPCN1)	INS_11268	INS chr12:113724222 (len:69 maf:0.0384268)	0.67	Lewy Body disease	4.35E-02
chr14:52798853-53900629 (FERMT2)	INV_1034	INV chr14:53274515 (len:179 maf:0.084991)	0.41	Cerebral Atherosclerosis	1.28E-02
chr15:58522615-59557023 (ADAM10)	DEL_9672	DEL chr15:58912865 (len:-329 maf:0.344033)	0.39	Global parkinsonian score	1.31E-01
chr16:19308163-20308163 (IQCK)	DEL_10481	DEL chr16:19945550 (len:-22029 maf:0.142405)	0.44	Major Depressive Disorder	2.34E-03
chr17:17559454-18559454 (MYO15A)	DEL_11664	DEL chr17:18270187 (len:-1505 maf:0.0863472)	0.37	TDP-43	7.02E-03

AD GWAS -log10(P-value)	Number of SVs in the locus	SV in LD with GWAS SNP (R2)	SV-xQTL (number of phenotypes)	SVs associated with AD/DRD phenotypes P-value < 0.005 (FDR/MAP)
chr1:485377-1485377 (AGRN)	7.4	21	2	3
chr1:109388432-110388432 (SORT1)	8.1	7	1	3
r1:160655392-161655392 (ADAMTS4)	9.7	5	1	1
chr1:207192049-208302552 (CR1)	23.2	6		1
chr2:9199011-10199011 (ADAM17)	7.6	11		1
chr2:37031939-38031939 (PRKD3)	8.5	3		
chr2:105735428-106866056 (NCK2)	12.7	12	3	
chr2:127391427-128392810 (BIN1)	43.2	4		1
chr2:203243439-204243439 (WDR12)	8	3		2
chr2:233481912-234582577 (INPP5D)	7.5	15		1
chr3:56726150-57726150 (HESX1)	7.9	5		1
chr3:154287511-155301978 (MME)	10.7	5	1	
chr4:487343-1487343 (DUA)	11.1	32	2	1
chr4:10514822-11526028 (CLNK)	16.7	7		
chr4:39698846-40698846 (RHOF)	8.9	8		
chr5:14224413-15224413 (ANKH)	8.6	6	1	1
chr5:85723195-86723195 (COX7C)	14.9	9		
chr5:87723420-88723420 (MEF2C)	7.5	3		
chr5:149932388-150932388 (TNIP1)	8.9	4		1
chr5:156026331-157026331 (HAVCR2)	9.1	2		
5:179128150-180128150 (RASGEF1C)	15.7	9		1
chr6:32075406-33083813 (HLA-DQA1)	11.5	75	0.91	3
chr6:40442196-41654650 (TREM2)	36.6	12		1
chr6:46931284-48052180 (CD2AP)	10.3	6	0.22	1
chr6:114112895-115112895 (HS3ST5)	8.6	3		
chr7:7356894-8744012 (CA1)	8.2	9		1
chr7:11768758-12769593 (TMEM106B)	8.6	11	0.96	2
chr7:27668746-28668746 (JAZF1)	8	2		
chr7:37341534-38383793 (EPDR1)	9.3	9		1
chr7:54441328-55441328 (SEC61G)	9.8	13		1
chr7:99432049-100591795 (SPDY3)	15	8		2
chr7:142599133-143610762 (EPHA1)	10.3	4		1
r7:145450029-146450029 (CNTNAP2)	8.7	6		
chr8:11202122-12202122 (CTSB)	8.7	4		2
chr8:26695121-27967686 (PTK2B)	13.1	11		1
hr8:144608151-145658607 (SHARPIN)	15.8	17		3
chr9:107165978-108165978 (ABCA1)	8.8	10		1
chr10:11217397-12223008 (ECHDC3)	10.7	7		3
chr10:61238152-62284928 (ANK3)	7.4	4		
chr10:81753984-82753984 (TSPAN14)	18.7	4		
chr10:97526407-98526407 (BLNK)	10.2	6		2
r10:123672912-124672912 (PLEKHA1)	8.6	3	0.23	1
chr11:46880340-48057871 (CELF1)	8	9	0.56	1
chr11:59423508-60521948 (MS4A4A)	32.5	7		
chr11:85276544-86368640 (PICCALM)	25.9	9		2
chr11:120853077-121935587 (SORL1)	10.6	5		1
chr12:113219788-114219788 (TPCN1)	8.7	8	0.67	1
chr14:52798853-53900629 (FERMT2)	8.9	6	0.41	2
chr14:92426952-93438855 (SLC24A4)	7.3	2		1
r14:105728095-107621607 (TMEM121)	7.7	35		3
chr15:50494011-51501534 (SPPL2A)	7.9	9		3
chr15:58522615-59557023 (MINDY2)	14.2	4	0.39	2
chr15:63069902-64923506 (APH1B)	24.7	6		1
chr15:78729199-79729199 (CTSH)	8.4	5		1
chr16:19308163-20308163 (IQCK)	7.6	9	0.44	2
chr16:29521402-30521402 (DOC2A)	12.6	2		1
chr16:30622571-31633100 (KAT8)	7.4	4		1
chr16:70194000-71194000 (IL34)	7.4	2		4
chr16:78855857-80108408 (WWOX)	7.4	5		1
chr16:81273003-82442028 (PLCG2)	12.9	11		1
chr16:85954210-86954210 (FOXF1)	7.9	15		4
chr16:89670095-90670095 (PRDM7)	14.2	15		2
chr17:1131341-2131341 (WDR81)	10.1	17		2
chr17:4469940-5638990 (SCIMP)	11.2	17		2
chr17:17559454-18559454 (MYO15A)	9	6	0.37	1
chr17:41930244-42942344 (GRN)	19.6	1		1
chr17:44356641-45356641 (WNT3)	12	3		1
chr17:46797297-47950775 (AB13)	13.6	8		
chr17:55909089-56910041 (TSPOAP1)	9.1	3		1
chr17:61038148-62048918 (CYB561)	8.3	4		1
chr18:55689459-56689459 (ALPK2)	7.5	5		1
chr19:539323-2354258 (ABCA7)	15.5	47		3
chr19:44851516-4674841 (APOE)	300	16		2
chr19:48713504-49713504 (MAMSTR)	7.8	13		2
chr19:49953317-50953317 (SIGLEC11)	8.3	7		2
chr19:51227962-52237991 (CD33)	9.7	10		
chr19:54271451-55325174 (LILRB2)	10.4	18		3
chr20:1-893978 (RBCK1)	7.8	7		1
chr20:54483075-55518260 (CASS4)	15.2	6		1
r20:61874441-62874441 (SLC2A4RG)	8.6	29		2
chr21:26769932-28658856 (APP)	9.1	10		1

### Supplementary Figure S1. Overview of SVs in 81 AD GWAS loci.

Heatmap shows for each of the AD loci (row): 1) the strength of the association in the GWAS study; 2) the number of SVs in the region; 3) the strength of LD between the lead GWAS SNP and an SV (highest R2); 4) the number of AD/DRD phenotypes associated in the SV-GWAS tests; 5) the number of molecular phenotypes linked to an SV found in each locus (SV-xQTL).